Develops a drug called P140 that targets a specific molecular switch to treat lupus and CIDP in patients identified through a paired diagnostic test.
ImmuPharma is developing a drug called P140 that treats lupus and CIDP by blocking a specific molecular event — the phosphorylation of a ribosomal protein called P0 — that drives the immune system to attack the body. Because only some patients with these conditions actually carry that phosphorylation signature, a companion diagnostic test must screen each patient before they can receive the drug, which means the test and the drug were built as a pair and must be approved by the FDA and EMA together — neither can reach patients without the other. The patent on the P0 phosphorylation mechanism runs until 2045, so no competitor can legally replicate the same approach, and any rival would need to find a different molecular target, build a new diagnostic from scratch, and run the entire joint approval process again. The whole structure depends on clinical trials confirming that blocking P0 phosphorylation actually restores immune balance in patients, because if that result fails to materialise, both the drug and the diagnostic are invalidated at once and there is no fallback target within the current platform.
How does this company make money?
The company currently has no revenue — it is still in clinical trials. If P140 and the companion diagnostic receive regulatory approval, the plan is to earn money through per-unit sales of P140 via specialty pharmacy channels and through licensing fees paid by providers who use the companion diagnostic to select patients for precision autoimmune treatment.
What makes this company hard to replace?
Because the companion diagnostic and P140 are approved as a joined pair by both the FDA and EMA, a clinical site cannot simply swap in a different drug and keep using the same test, or vice versa. Each site must also be specifically trained on the autophagy biomarker protocol before they can screen or treat patients, which creates a real operational commitment. And because the ribosomal protein P0 phosphorylation pathway is under patent until 2045, no competing drug using the same mechanism will legally exist during that period.
What limits this company?
Only the subset of lupus and CIDP patients whose tests show active P0 phosphorylation are eligible. Before any of those patients can even be enrolled in a trial, each clinical site must be trained on the specific autophagy biomarker screening protocol. Every new site added requires that training first, so growth in trial enrollment is gated by how quickly sites can be brought up to speed.
What does this company depend on?
The company cannot operate without peptide synthesis facilities that can manufacture P140 to clinical-grade specifications, the companion diagnostic technology used to screen patients, clinical research organizations running the lupus and CIDP trials, the FDA and EMA regulatory pathways for orphan autoimmune diseases, and the patent protection covering the autophagy immunomodulator mechanism through 2045.
Who depends on this company?
Lupus patients currently in clinical trials who are receiving P140 as a potential path to disease remission rather than just symptom control would lose access to that option if development stopped. CIDP patients waiting for alternatives to existing immunosuppressive therapies would have no equivalent candidate. Specialty rheumatology and neurology centers running precision autoimmune treatment programs would lose access to this entire therapeutic approach.
How does this company scale?
Once the P140 mechanism and companion diagnostic algorithms are validated in trials, they can in principle be applied across patient populations without rebuilding the science each time. What does not scale automatically is the team: the current six-person London operation cannot run multiple clinical programs or pursue regulatory submissions in several regions at the same time without hiring significantly more specialist clinical development staff.
What external forces can significantly affect this company?
The UK's post-Brexit position outside the EMA creates ongoing uncertainty about how European clinical trial coordination will work, since UK and EU rules no longer move in lockstep. Healthcare reimbursement policies for precision autoimmune drugs in major markets will determine whether approved products can actually be sold at prices that sustain the business. Currency swings between GBP and USD add unpredictable cost variation across trial sites operating in different countries.
Where is this company structurally vulnerable?
If the pivotal clinical trials show that blocking P0 phosphorylation does not actually restore immune balance in lupus or CIDP patients, the entire structure falls apart at once. The drug loses its scientific basis, the companion diagnostic loses its purpose, and the patent on the pathway becomes commercially worthless — all at the same time, with no backup target inside the current platform.
Sign in to view price data.
Sign inAs of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph